Talquetamab and Its Effect on Relapsed and Refractory Multiple Myeloma.
ABSTRACT Relapsed and refractory multiple myeloma (RRMM) remains a challenging condition despite many advances in immunotherapies. Outcomes are particularly dismal in patients who are refractory to these three major classes of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies (mAbs), and chimeric ant...